Formulation approaches in enhancement of patient compliance to oral drug therapy

Expert Opinion on Drug Delivery

Volumn 8, Issue 11, 2011, Pages 1521-1529

  Shahiwala, Aliasgar ^a  

^a DUBAI PHARMACY COLLEGE   (United Arab Emirates)

Author keywords

Intraoral drug delivery; Patient compliance; Patient convenience; Taste masking

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ARTEMETHER; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CAFFEINE; CHLORHEXIDINE; CISAPRIDE; DEXAMETHASONE; DEXTROMETHORPHAN; DIMENHYDRINATE; DIMETAPP; DIPHENHYDRAMINE; DIURETIC AGENT; ENDEKAY; EXCEDRIN; FAMOTIDINE; FLUOGUM; FLUORIDE; FLURBIPROFEN; GAS X; GASTER D; LINDANE; LORATADINE; MULTIVITAMIN; NICOTINE; NICOTINE GUM; NON PRESCRIPTION DRUG; ONDANSETRON; PRIMAQUINE; RISPERIDONE; SELEGILINE; SIMETHICONE; STAY ALERT; STREFEN; STREPSILS; THERAFLU; TRAWEL GUM; TRIAMINIC; UNCLASSIFIED DRUG; VICKS; ZOLMIG; ZOLMITRIPTAN;

CHEMOTHERAPY INDUCED EMESIS; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DYSPHAGIA; HUMAN; LOZENGE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTOPERATIVE NAUSEA AND VOMITING; RADIATION SICKNESS; REVIEW; TABLET DISINTEGRATION; TABLET FORMULATION; TASTE;

ADMINISTRATION, ORAL; ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHILD; DEGLUTITION DISORDERS; HUMANS; MEDICATION ADHERENCE; PATIENT PREFERENCE; PHARMACEUTICAL PREPARATIONS; TASTE;

EID: 80054797024     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.628311     Document Type: Review

References (69)

1. Ngoh LN. Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc 2009;49(5):e132-46
2. Elliott RA, Marriott JL. Standardized assessment of patients' capacity to manage medications: a systematic review of published instruments. BMC Geriatr 2009;9:27
3. Mattar ME, Markello J, Yaffe SJ. Pharmaceutic factors affecting pediatric compliance. Pediatrics 1975;55:101-8
4. Boreham PFL, Benrimoj S, Ong M, et al. A compliance study in pediatric patients receiving treatment for giardiasis. Aust J Hosp Pharm 1986;16:138-42 (Pubitemid 17186724)
5. Fincham JE. Patient compliance in the ambulatory elderly: a review of the literature. J Geriatr Drug Ther 1988;2(4):31-52
6. Goldfarb J, Patel J, Wormser G. Antimicrobial flavors: a consideration in drug compliance. Drug Ther 1986;2:59-71
7. Weinstein AG. Clinical management strategies to maintain drug compliance in asthmatic children. Ann Allergy Asthma Immunol 1995;74:304-10
8. Fennell RS, Foulkes L-M, Boggs SR. Family-based program to promote medication compliance in renal transplant children. Transplant Proc 1994;26:102-3 (Pubitemid 24080437)
9. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59(6):674-6 (Pubitemid 40835500)
10. Kumazawa T, Nomura T, Kurihara K. Liposomes as model for taste cells: receptor sites for bitter substances including N-C S substances and mechanism of membrane potential changes. Biochemistry 1988;27:1239-44
11. Sugao H, Yamazaki S, Shiozawa H, Yano K. Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax-coated microparticles. J Pharm Sci 1998;87:96-100 (Pubitemid 28079269)
12. Hashimoto Y, Tanaka M, Kishimoto H, et al. Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine. J Pharm Pharmacol 2002;54:1323-8 (Pubitemid 35174176)
13. Nanda A, Kandarapu R, Garg S. An update on taste masking technologies for oral pharmaceuticals. Indian J Pharm Sci 2002;64:10-17
14. Keast RSJ, Breslin PAS. Bitterness suppression with zinc sulfate and Nacclamate: a model of combined peripheral and central neural approaches to flavor modification. Pharm Res 2005;22:1970-7 (Pubitemid 41504350)
15. Fu Y, Yang S, Jeong SH, et al. Critical reviews- in therapeutic drug carrier systems. Crit Rev Ther Drug 2004;21(6):433-75; Orally Fast Disintegrating Tablets: Developments, Technologies, Taste-Masking and Clinical Studies
16. Kleinert HD, Baker WR, Stein HH. Ion exchange resin complexes: an approach to mask the taste of bitter drugs. Pharm Technol 1993;17:30
17. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin Drug Deliv 2007;4(4):417-26 (Pubitemid 47249139)
18. Anderson O, Zweidorff OK, Hjelde T. Problems when swallowing tablets. A questionnaire study from general practice [in Norwegian]. Tidsskr Nor Laegeforen 1995;20:947-9
19. Slowson M, Slowson S. What to do when patients cannot swallow their medications. Pharm Times 1985;51:90-6
20. Lindgren S, Janzon L. Dysphagia: prevalence of swallowing complaints and clinical findings. Med Clin N Am 1993;77:3-5
21. Chang RK, Guo X, Burnside BA. Fast-dissolving tablets. Pharm Technol 2000;24(6):52-8 (Pubitemid 30450499)
22. Rathbone MJ, Drummond BK, Tucker IG. The oral cavity as a site for systemic drug delivery. Adv Drug Deliv Rev 1994;13:1-22 (Pubitemid 24032039)
23. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with Sjeogren's syndrome. Oral Surg Oral Med Oral Pathol 1991;72:545-9
24. Gmunder CB, Li W, Ream R, et al. Sildenafil chewing gum formulations and methods of using the same. US6592850B2; 2003
25. Liang AC, Chen LH. Fast-dissolving intraoral drug delivery systems. Expert Opin Ther Patents 2001;11(6):981-6 (Pubitemid 32536833)
26. Brown D. Orally disintegrating tablets: taste over speed. Drug Deliv Technol 2003;3(6):58; 61.13
27. Ghosh TK, Pfister WR. Drug delivery to the oral cavity: molecules to market. Marcel Dekker, Inc.; New York: 2005
28. Seager H. Drug delivery products and Zydis- fast dissolving dosage form. Presented at the British Pharmaceutical Conference; September 1997; Scarborough
29. Yarwood R. Oral fast dissolving dosage form technologies. Presented at IBC symposium on drug delivery systems; July 17-18, 1997; San Francisco
30. Wehling F, Schuehle S. Base coated acid particles and effervescent formulations incorporating same. US5503846, 1993
31. Wehling F, Schuehle S, Madamala N. Pediatric effervescent dosage. US5223264, 1991
32. Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, tastemasking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004;21:433-76
33. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapidly disintegrating tablets. AAPS PharmSciTech 2007;8:article 46
34. William N. Anti-infective. In: Gennaro AR, editors. Remington's: the Science and Practice of Pharmacy. Volume 2 Lippincott Williams and Wilkins; Philadelphia, PA: 1547
35. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondensetron hydrochloride by polymer carrier system and formulation of rapidly disintegrating tablets. AAPS PharmSciTech 2007;8:article 46
36. Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004;21:433-76
37. Shah PP, Mashru RC. Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique. AAPS PharmSciTech 2008;9:494-500
38. Shah PP, Rajashree C. Mashru formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet. J Pharm Pharmacol 2008;60:1279-85
39. Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving films for delivery of Triclosan to the oral cavity. AAPS PharmSciTech 2008;9(2):349-56
40. Saigal N, Baboota S, Ahuja A, Ali J. Fast-dissolving Intraoral drug delivery systems. Expert Opin Ther Patents 2008;18(7):769-78
41. Habib W, Khankari R, Hontz J. Fast dissolve delivery system. Crit Rev Ther Drug Carrier Syst 2000;17:61-72
42. Biradar SS, Bhagavati ST, Kuppuasad IJ. Fast dissolving drug delivery systems: a brief overview. Internet J Pharmacol 2006;4:2
43. Shimoda H, Taniguchi K, Nishimura M, et al. Preparation of a fast dissolving oral thin film containing dexamethasone: a possible application to antiemesis during cancer chemotherapy. Eur J Pharm Biopharm 2009;73(3):361-5
44. Kelly F. Something for a sore throat please. Aust Pharm 2008;27:394-7
45. Hartung-Brooks L. Sore throat. On Contin Pract 1990;17:2-6 (Pubitemid 20094946)
46. Fincham JE. Smoking cessation products, Chapter 36. In: Covington TR, editor. Handbook of Nonprescription Drugs. American Pharmaceutical Association; Washington, DC: 1996. p. 715-23
47. Houtsmuller EJ, Fant RV, Eissenberg TE, et al. Flavor- improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 2002;72(3):559-68
48. Christrup LL, Davis SS, Frier M, et al. Deposition of a model substance, 99mTcE-HIDA, in the oral cavity after administration of lozenges, chewing gum and sublingual tablets. Int J Pharm 1990;66:169-74
49. Chaudhri S, Shahiwala A. Medicated chewing gums: a promising drug delivery system. Expert Opin Drug Deliv 2010;7(7):871-85
50. Richards RME, Cowie G, McCague GJ. In vivo investigations of the antibacterial activity of lozenges and mouthwashes on the aerobic bacterial flora of the mouth and throat. Pharm J 1989;6:58-63
51. Richards RME, Xing DKL. In vitro evaluation of the antimicrobial activities of selected lozenges. J Pharm Sci 1993;82:1218-20
52. Stanley TH, Hague BH, Mock DL, et al. Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. Anaesth Analg 1989;69:21
53. Streisand JB, Stanley TH, Hague B, et al. Oral transmucosal fentanyl citrate premedication in children. Anaesth Analg 1989;69:28
54. Friesen RH, Lockhart CH. Oral transmucosal fentanyl citrate for preanesthetic medication of pediatric day surgery patients with and without droperidol as a prophylactic anti-emetic. Anesthesiology 1992;76:46
55. Feld LH, Champeau MW, van Steennis CA, et al. Preanesthetic medication in children: A comparison of oral transmucosal fentanyl citrate versus placebo. Anesthesiology 1989;71:374
56. Goldstein-Dresner MC, Davis PJ, Kretchman E, et al. Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. Anesthesiology 1991;74:28
57. Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984;35:742-9 (Pubitemid 14077477)
58. Kleinbloesem CH, van Brummelen P, Danhof M, et al. Rate of increase in plasma concentration of nifedipine as a major determinant of its haemodynamic effects in man. Clin Pharmacol Ther 1987;41:407-12
59. Cramer JA, Lynch NO, Gaudin A-F, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of Studies in the United States, the United Kingdom, and France. Clin Ther 2006;28(10):1686-94 (Pubitemid 44838898)
60. Ritschel WA, Forusz H. Chronopharmacology: a review of drugs studies. Methods Find Exp Clin Pharmacol 1994;16(1):57-75
61. Lemmer B. Chronobiology, drug-delivery, and chronotherapeutics. Adv Drug Deliv Rev 2007;59:825-7 (Pubitemid 47531901)
62. Smolensky MH, Peppas NA. Chronobiology, drug delivery and chronotherapeutics. Adv Drug Deliv Rev 2007;59:828-51
63. Lemmer B. Chronopharmacology and controlled drug release. Expert Opin Drug Deliv 2005;2(4):667-81 (Pubitemid 41038679)
64. Mandal AS, Biswas N, Karim KM, et al. Drug delivery system based on chronobiology-A review. J Control Release 2010;147(3):314-25
65. Janice M. Reichert trends in US approvals: new biopharmaceuticals and vaccines. Trends Biotechnol 2006;24(7):293-8
66. Walters KA. Drug delivery: topical and transdermal routes. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology. 3rd edition. Volume 1 Informa healthcare; New York: p. 1311-25, 2007
67. Rogers K. Controlled release technology and delivery systems. Cosmet Toilet 1999;114(5):53-60
68. Touitou E, Dayan N, Bergelson L, et al. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000;65:403-18 (Pubitemid 30122942)
69. Tao L. Skin delivery from lipid vesicles. Cosmet Toilet 2000;115(4):43-50